Tag - gilead

 
Menu
Search
 
April 16, 2024
 

Today's print edition

Home Delivery
Subscribe for more access

GILEAD

Japan Times
WORLD / Science & Health
Nov 20, 2020
WHO advises doctors not to use Gilead’s remdesivir for COVID-19
The recommendation is a blow to Gilead's drug, which was one of the first thought to offer a meaningful benefit in treatment of coronavirus patients.
Japan Times
BUSINESS / Companies
Jun 23, 2020
Gilead targets remdesivir supply for 2 million COVID-19 patients by year-end
The company also said it hoped to start trials in August of an easier-to-use inhaled version of the medicine, which is currently administered only intravenously.
Japan Times
WORLD / Science & Health
May 23, 2020
Gilead’s remdesivir mainly helped healthier COVID-19 patients
Gilead Sciences Inc.’s remdesivir, the first medicine cleared for the treatment of COVID-19, mainly benefited healthier patients who weren’t dependent on ventilators or heart-lung bypass machines, according to published results of the study used to get the medicine on the market.
Japan Times
WORLD / Science & Health
May 2, 2020
U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir
Gilead Science Inc.'s antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday, clearing the way for broader use of the drug in more hospitals around the United States.
Japan Times
WORLD / Science & Health
May 1, 2020
Virus drugmaker caught between making a profit and treating the world
Gilead Sciences Inc. may spend $1 billion on its breakthrough new treatment for COVID-19 this year alone, Chief Executive Officer Daniel O’Day said. How much revenue — if any — the company expects to generate is another matter.
Japan Times
JAPAN / Science & Health
Apr 28, 2020
Remdesivir drug to be approved for coronavirus patients in May
This is the first time the government has used the streamlined process since the pandemic started.
Japan Times
WORLD / Science & Health
Apr 11, 2020
Two-thirds of severe COVID-19 cases improved with remdesivir drug
Gilead Sciences Inc.’s experimental drug for patients with severe COVID-19 infections showed promise in an early analysis, raising tentative hope that the first treatment for the novel virus may be on the horizon.
BUSINESS
Feb 26, 2020
U.S. begins first coronavirus clinical trial testing Gilead's experimental drug
U.S. health officials said on Tuesday the first clinical trial testing Gilead Sciences Inc.'s experimental antiviral drug, remdesivir, in hospitalized patients with the coronavirus has started.
Japan Times
ASIA PACIFIC / Science & Health
Feb 14, 2020
Gilead drug prevents type of coronavirus in monkeys, raising hope for China trials
An experimental Gilead Sciences antiviral drug prevented disease and reduced the severity of symptoms in monkeys infected with Middle East respiratory syndrome (MERS), an infection closely related to the fast-spreading coronavirus that originated in China, a study published on Thursday found.
Japan Times
ASIA PACIFIC / Science & Health
Feb 1, 2020
Coronavirus case in U.S. treated with Gilead drug may spur wider tests
The first reported use of an experimental Gilead Sciences Inc. drug to fight the novel coronavirus has encouraged doctors to support further testing of the medication.
JAPAN / Science & Health
Aug 27, 2015
Japan health ministry approves new hepatitis C drug under insurance scheme
The tablet drug Harvoni is expected to revolutionize the treatment of patients with hepatitis C genotype 1, which accounts for about 70 percent of all hepatitis C patients in Japan.
Japan’s young workers head abroad as huge wage gap persists
The departure hall at Haneda Airport in Tokyo. Now with inflation at its strongest in decades, Japanese are starting to realize that years of static wages leave many of them budgeting each month before their next pay check.
Akebono's human side eclipsed his incredible sumo achievements
The heights Akebono reached in sumo helped pave the way for future foreign-born yokozuna Asashoryu and Hakuho.
EVs head for junkyard as mechanic shortage inflates repair costs
An AA patrol for electric vehicles in Birmingham, England. Fewer than 10% of the U.K.’s 236,000 auto mechanics are qualified to work directly on EV batteries or their cases, according to the Institute of the Motor Industry.
Japan strongly condemns Iranian attack on Israel as 'escalation'
Missiles are showcased in a parade marking Iran's National Army Day in Tehran on April 18, 2023.
Death-row inmates' lawsuit targeting same-day notifications of executions dismissed
Two plaintiffs filed a lawsuit with Osaka District Court in hopes of sparking a wider discussion on the rights of death row prisoners.
For Modi, the Indian election is less about winning and more about by how much
Indian Prime Minister Narendra Modi addresses supporters during an election campaign rally in Pushkar, India, on April 6, ahead of the country's upcoming general election starting Friday.
Akebono's human side eclipsed his incredible sumo achievements
The heights Akebono reached in sumo helped pave the way for future foreign-born yokozuna Asashoryu and Hakuho.
Ohtani’s dizzying three weeks end in exoneration by authorities
Los Angeles Dodgers designated hitter Shohei Ohtani during a spring training game on March 12.
How ‘winged’ gyōza took flight from a Tokyo suburb
The creator of "hanetsuki gyōza" is Isao Yagi, and his restaurant, Nihao, can be found right on the border of Tokyo and Kawasaki in Ota Ward.
How Ippei Mizuhara allegedly wired millions from Shohei Ohtani’s account
Dodgers star Shohei Ohtani and his interpreter, Ippei Mizuhara, in December at SoFi Stadium in Inglewood, California

Podcast

Two people try to take a selfie under the illuminated cherry blossoms in Kyoto’s Gion district last year.
Sakura stories revisited: Getting in the mood for hanami

Longform

Historically, kabuki was considered the entertainment of the merchant and peasant classes, a far cry from how it is regarded today.
For Japan's oldest kabuki theater, the show must go on
By Lance Henderstein

SUSTAINABLE JAPAN

Vol. 34: Tokyo, a vanguard city for sustainability
Vol. 34: Tokyo, a vanguard city for sustainability

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER